Insider trade

Officer sold ~$112K of ALKS shares in the open market

Traded Dec 3, 2025 · Filed Dec 5, 2025

Why it stands out

Alkermes's R&D, Chief Medical Officer sold $112K of Alkermes shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$112,447

Shares × reported transaction price

Timing vs results

36 days after results of Oct 28, 2025, 40 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−4.2%	−0.4%	−3.8%
30 days	−0.2%	+0.9%	−1.0%
90 days	−3.3%	−0.8%	−2.5%
180 days	+44.3%	+8.1%	+36.2%

Past results only. Not a forecast.

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.